Overview

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Status:
Not yet recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Carboplatin
Cyclophosphamide
Epirubicin
Goserelin
Letrozole
Paclitaxel
Pertuzumab
Trastuzumab